Literature DB >> 31292940

C1QTNF6 as a novel biomarker regulates cellular behaviors in A549 cells and exacerbates the outcome of lung adenocarcinoma patients.

Min Han1, Bo Wang1, Min Zhu2, Yue Zhang3.   

Abstract

C1q/tumor necrosis factor-related protein 6 (C1QTNF6) is a member of the CTRP family and implicated to cardiovascular diseases, inflammatory reaction, and adipogenesis. However, the function of C1QTNF6 in lung adenocarcinoma remains unknown. We downloaded the expression profiles of C1QTNF6 from TCGA database and Oncomine dataset in order to analyze the relationship between C1QTNF6 expression level and tumorigenesis by bioinformatics methods, such as chi-square test, Kaplan-Meier, and Cox regression analysis. In addition, we performed experiments to investigate the biological function of C1QTNF6 on cancer cells in vitro. The siRNA strategy was conducted to decrease the C1QTNF6 expression and then Cell Counting Kit-8 (CCK8) assay and wound-healing and transwell assays were to determine the proliferation, migration, and invasion. Western blot and qRT-PCR were used to confirm the expression levels. Based on the TCGA database and Oncomine dataset, we found that C1QTNF6 was over expressed in lung adenocarcinoma. The statistical data also showed that the high-regulated C1QTNF6 was related to poor prognosis in patients with lung adenocarcinoma. Moreover, the capabilities of proliferation, migration, and invasion were inhibited owing to the knockdown of C1QTNF6 in lung adenocarcinoma cells. And the phosphorylation of MEK and ERK was blocked by treated si-C1QTNF6 compared with the GAPDH. In conclusion, aberrant C1QTNF6 expression was implicated in terrible prognosis accompanying with the damage of relevant cell potential in lung adenocarcinoma. C1QTNF6 might be an independent predictor of prognosis in lung adenocarcinoma.

Entities:  

Keywords:  C1QTNF6; Cell viability; Lung adenocarcinoma; Prognosis

Year:  2019        PMID: 31292940     DOI: 10.1007/s11626-019-00377-w

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  7 in total

1.  C1QTNF6 regulates cell proliferation and apoptosis of NSCLC in vitro and in vivo.

Authors:  Wei Zhang; Ganzhu Feng
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

2.  A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining.

Authors:  Jie Liu; Shiqiang Hou; Jinyi Wang; Zhengjun Chai; Xuan Hong; Tian Zhao; Zhengliang Sun; Liandi Bai; Hongyan Gao; Jing Gao; Guohan Chen
Journal:  Oxid Med Cell Longev       Date:  2020-12-19       Impact factor: 6.543

3.  C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis.

Authors:  Wei Liu; Jian Zhang; Tao Xie; Xiaoting Huang; Baiyao Wang; Yunhong Tian; Yawei Yuan
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

4.  A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma.

Authors:  Xiahui Yang; Minchao Liang; Zhiqi Yu; Jiaquan Fan
Journal:  J Oncol       Date:  2022-07-30       Impact factor: 4.501

5.  ANKRD49 promotes the invasion and metastasis of lung adenocarcinoma via a P38/ATF-2 signalling pathway.

Authors:  Yue-Hua Liu; Meng Yuan; Bai-Xue Xu; Rui Gao; Yu-Jie You; Zhi-Xin Wang; Yong-Cai Zhang; Min Guo; Zhao-Yang Chen; Bao-Feng Yu; Qi-Wei Wang; Hai-Long Wang; Min Pang
Journal:  J Cell Mol Med       Date:  2022-06-30       Impact factor: 5.295

6.  C1QTNF6 regulated by miR-29a-3p promotes proliferation and migration in stage I lung adenocarcinoma.

Authors:  Guofu Lin; Lanlan Lin; Hai Lin; Yingxuan Xu; Wenhan Chen; Yifei Liu; Jingyang Wu; Shaohua Chen; Qinhui Lin; Yiming Zeng; Yuan Xu
Journal:  BMC Pulm Med       Date:  2022-07-25       Impact factor: 3.320

7.  Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma.

Authors:  Yingqing Zhang; Xiaoping Zhang; Xiaodong Lv; Ming Zhang; Xixi Gao; Jialiang Liu; Yufen Xu; Zhixian Fang; Wenyu Chen
Journal:  Biomed Res Int       Date:  2020-08-17       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.